miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 1, 2026

Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more

View original at seekingalpha.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more [February 2026 Yellow Desk Calendar Among Office Supplies] spawns/iStock via Getty Images Earnings season rolls into a high-impact week ahead, with results due from a broad cross-section of the market spanning Big…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pfizer remains firmly in the green zone into 2026, with the bullish case resting on oncology and vaccine pipeline alongside potentially best-in-class GLP-1/amylin candidates

    80% confidence
  • While PM now trades closer to fair value, further upside hinges on upgraded guidance, supporting a continued Buy stance

    80% confidence
  • Alphabet downgraded to Hold, noting that shares have nearly doubled in a year and appear fully priced

    80% confidence
  • Disney remains a Buy with strong FY26-FY27 EPS growth guidance and attractive valuations suggesting meaningful upside

    80% confidence
  • Pfizer's 2026 guidance implies continued Y/Y declines, with revenue and EPS midpoints of $61B and $2.90, respectively

    80% confidence
  • Amazon is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum, and improving DTC fundamentals

    80% confidence
  • Pfizer maintains a Sell rating citing persistent margin and growth headwinds

    80% confidence
  • Philip Morris strong execution has driven a 108% total return since January 2024, more than double the S&P 500

    80% confidence
  • Expectations are building for higher capital deployment (~$29B) and potentially ~44% growth in Google Cloud in early 2025

    80% confidence
  • Disney is benefiting from resilient theme park performance despite competitive headwinds, solid theatrical momentum from franchises like Avatar and Zootopia 2, and improving DTC fundamentals driven by subscriber growth and expanding ARPUs

    80% confidence
  • PFE trades at just ~8.5x forward non-GAAP earnings, well below peers such as AbbVie, Merck, and Eli Lilly, while offering a dividend yield north of 6%

    80% confidence
  • Valuation multiples sit at multi-decade highs, with EV/EBITDA near 26x and FCF yield compressed to ~1.8%

    80% confidence
  • Alphabet is a Buy with a $331 price target, pointing to accelerating Gemini AI adoption and expanding Google Cloud margins

    80% confidence
  • Philip Morris reaffirmed its FY2025 profit guidance at Morgan Stanley Global Consumer & Retail Conference in December

    80% confidence
  • Applying a conservative 16.5x EV/EBITDA multiple, AMZN still offers attractive upside, with margins and free cash flow expected to improve by 2026

    80% confidence
  • The rally has been driven primarily by robust ZYN growth, with nicotine pouch volumes up 36% Y/Y

    80% confidence
  • Amazon remains a Strong Buy with a $319.56 price target and 32% upside, despite recent underperformance versus the S&P 500

    80% confidence

Data points we hold from this source

The Walt Disney Company · revenue25.60 billion_USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Earnings week ahead: AMZN, GOOG, PLTR, AMD, PFE, DIS, PYPL, ABBV, QCOM, SMCI, MRK, PEP, UBER, PM, and more — Source | Via News | es.VIA.NEWS